Glaxo Wellcome is holding pitches for agencies to handle PR for its
main UK therapy areas on combined fees of at least pounds 300,000.
Pitches for three UK product PR accounts are being held, while one
pan-European account is known to be the subject of an intense round of
Up for pitch is the UK over-the-counter (OTC) therapy range, which
includes products like Zantac 75, a treatment for indigestion, and
Zovirax, for treating cold-sores.
Agencies are also competing to handle UK PR for HIV treatments such as
Combivir, and several new products set to be launched.
The third UK PR account open to pitch is for influenza drug Relenza,
which is the first new treatment for flu for several years.
There are no incumbent agencies on any of these accounts.
Glaxo Wellcome communications manager Philip Thomson said: ’We are
looking for an agency that can offer creativity and an ability to think
strategically in the face of increasing competition.’
Manning Selvage and Lee, Chandler Chicco, Sante Communications, Shire
Hall, Hill and Knowlton, Countrywide Porter Novelli and Lowe Fusion
Healthcare are all on Glaxo Wellcome’s pitch roster.
Marketing plans are still being examined for other products within
neurology and psychiatry, and further PR accounts could be tendered.
Glaxo currently retains five agencies working on six separate
Chandler Chicco and Countrywide Porter Novelli share the UK PR account
for the respiratory therapy area, while Sante Communications was
appointed last week (PR Week 23, April) to run a global campaign for the
Sante Communications also promotes Glaxo’s neurology and psychiatric
range on a global basis. Lowe Fusion handles the migraine treatment
Shire Hall International handles global PR for Glaxo’s HIV therapy area.